Kasi PM - Search Results

1

Transition of Care for Inpatient Hematology Patients Receiving Chemotherapy: Development of Hospital Discharge Huddle Process and Effects of Implementation.

Warsame R, Kasi PM, Villasboas-Bisneto JC, Gallenberg D, Wolf R, Ward J, Matt-Hensrud N, Grethen K, Colborn L, Zeldenrust S, Lacy MQ, Thompson CA. Warsame R, et al. Among authors: kasi pm. J Oncol Pract. 2016 Jan;12(1):e88-94. doi: 10.1200/JOP.2015.005785. Epub 2015 Sep 15. J Oncol Pract. 2016. PMID: 26374861

2

Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer.

Kasi PM, Thanarajasingam G, Finnes HD, Villasboas Bisneto JC, Hubbard JM, Grothey A. Kasi PM, et al. Case Rep Oncol Med. 2015;2015:420159. doi: 10.1155/2015/420159. Epub 2015 May 21. Case Rep Oncol Med. 2015. PMID: 26090248 Free PMC article.

3

Should Vital Signs Be Routinely Obtained Prior to Intravenous Chemotherapy? Results From a 2-Center Study.

Menon S, Foster NR, Looker S, Sorgatz K, Kasi PM, McWilliams RR, Jatoi A. Menon S, et al. Among authors: kasi pm. Cancer Control. 2015 Oct;22(4):515-9. doi: 10.1177/107327481502200419. Cancer Control. 2015. PMID: 26678980 Free article.

4

Chemotherapy Maintenance.

Kasi PM, Grothey A. Kasi PM, et al. Cancer J. 2016 May-Jun;22(3):199-204. doi: 10.1097/PPO.0000000000000195. Cancer J. 2016. PMID: 27341599 Review.

5

Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients.

Kasi PM, Grothey A. Kasi PM, et al. Drugs. 2018 May;78(7):737-745. doi: 10.1007/s40265-018-0909-3. Drugs. 2018. PMID: 29754293 Review.

6

A Care Process Model to Deliver ¹⁷⁷Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors.

Kasi PM, Maige CL, Shahjehan F, Rodgers JM, Aloszka DL, Ritter A, Andrus ML, Mcmillan JM, Mody K, Sharma A, Jain MK. Kasi PM, et al. Front Oncol. 2019 Jan 9;8:663. doi: 10.3389/fonc.2018.00663. eCollection 2018. Front Oncol. 2019. PMID: 30687638 Free PMC article.

7

Treatment of HIV/AIDS associated cancers with immunotherapy targeting PD-1/PD-L1 instead of chemotherapy.

Kasi PM, Block MS, Ansell SM. Kasi PM, et al. Med Hypotheses. 2016 Jan;86:129-31. doi: 10.1016/j.mehy.2015.11.003. Epub 2015 Nov 5. Med Hypotheses. 2016. PMID: 26559886

8

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.

Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T. Kasi PM, et al. BMC Cancer. 2016 Jul 13;16:467. doi: 10.1186/s12885-016-2491-y. BMC Cancer. 2016. PMID: 27412464 Free PMC article.

9

The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study.

Elias AW, Kasi PM, Stauffer JA, Thiel DD, Colibaseanu DT, Mody K, Joseph RW, Bagaria SP. Elias AW, et al. Among authors: kasi pm. Front Oncol. 2017 Jun 12;7:121. doi: 10.3389/fonc.2017.00121. eCollection 2017. Front Oncol. 2017. PMID: 28660171 Free PMC article.

10

Body Mass Index and Long-Term Outcomes in Patients With Colorectal Cancer.

Shahjehan F, Merchea A, Cochuyt JJ, Li Z, Colibaseanu DT, Kasi PM. Shahjehan F, et al. Among authors: kasi pm. Front Oncol. 2018 Dec 17;8:620. doi: 10.3389/fonc.2018.00620. eCollection 2018. Front Oncol. 2018. PMID: 30631753 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

140 results

Search Page